House Passes Framework for $3.5T Budget Bill That Will Include Key Drug Pricing Measures

The U.S. House this week passed a budget blueprint that will pave the way for a vote on a number of drug pricing measures. 340B providers hope to be spared from Medicaid pharmacy cuts.

The House of Representatives passed a $3.5 trillion budget framework bill on Tuesday that potentially clears the path for Democrats to make extensive changes to U.S. health care delivery, although the impact on the 340B program remains to be seen.

Read More »

Key House Democrats Keep Up Pressure on Insulin Manufacturers

U.S. House Energy & Commerce Committee Democratic leaders Frank Pallone (N.J.) and Diana DeGette (Colo.) have asked insulin manufacturers Lilly, Novo Nordisk, and Sanofi for information about their prices, revenues, and expenses.

U.S. House Energy & Commerce Committee Democratic leaders have sent letters to three major drug manufacturers demanding an explanation for the skyrocketing price of insulin. The E&C Committee has jurisdiction over the 340B program and plays an instrumental role on

Read More »

340B Entities Left Out of BMS’s $75 Million Settlement; Whistleblower Pursues Case Against Lilly

340B covered entities will get none of the $75 million Bristol Myers Squibb is paying to settle claims it underreported its average manufacturer prices (AMPs) in order to underpay Medicaid drug rebates. A whistleblower is pursuing a similar case against Lilly.

340B covered entities will get none of the $75 million Bristol Myers Squibb is paying California, 27 other states, and the federal government to settle claims it underreported its average manufacturer prices (AMPs) in order to underpay Medicaid drug rebates.

Read More »

Merck Defends and Hospitals Slam the Company’s Tougher 340B Contract Pharmacy Policy

Drug manufacturer Merck is defending and hospital groups are condemning the drug company's decision to impose mandatory conditions on 340B pricing when hospitals use contract pharmacies.

Drug manufacturer Merck says it is imposing mandatory conditions on 340B pricing when hospitals use contract pharmacies due to “very low” participation in its voluntary 340B program integrity initiative.

Groups that represent hospitals in the drug discount program say Merck

Read More »

340B to Be Key Agenda Item for Biden’s New HHS General Counsel Pick

President Biden has nominated civil rights attorney Sam Bagenstos to be HHS General Counsel.

President Biden has nominated current White House Office of Management and Budget (OMB) General Counsel Sam Bagenstos to be the U.S. Health and Human Services Department (HHS) General Counsel—a post that has had a growing role in defending the 340B

Read More »

Wisconsin Lawmakers Introduce 340B Anti-Discrimination Measure but Leave Out Most 340B Hospitals

Wisconsin Gov. Tony Evers (D) is pushing for passage of legislation to eliminate payer and pharmacy benefit manager (PBM) discrimination against health centers, critical access hospitals, Ryan White HIV/AIDS program grantees, and their contract pharmacies.

Wisconsin Gov. Tony Evers (D) is pushing for passage of a package of 13 “Less for Rx” bills to control prescription drug costs, including one to eliminate payer and pharmacy benefit manager (PBM) discrimination against certain 340B covered entities.

The

Read More »

340B Report Publisher and CEO Says New Bipartisan 340B Bill is Win for Providers and Drug Industry

The PROTECT 340B solves "two of the most intractable challenges in the 340B program in one fell swoop," 340B Report Publisher and CEO Ted Slafsky writes in his latest column for Omnicell.

U.S. Reps. David McKinley (R-W.Va.) and Abigail Spanberger’s (D-Va.) bipartisan PROTECT 340B Act (H.R. 4390) can “resolve two of the most intractable challenges in the 340B program in one fell swoop” while satisfying both covered entities and drug manufacturers, 340B

Read More »

Distressed Critical Access Hospitals that Devolve to Stay Open Would Lose 340B Eligibility

A new federal law to help financially distressed rural hospitals stay open in a reduced capacity would not preserve the hospitals’ eligibility for 340B drug discounts.

A new federal law to help financially distressed rural hospitals stay open in a reduced capacity would not preserve the hospitals’ eligibility for 340B drug discounts.

Federal spending legislation that President Trump signed into law last Dec. 27 included a

Read More »

Kalderos Urges Feds to Protect Hospitals from Losing 340B Eligibility During Pandemic

Drug industry vendor Kalderos is urging leaders in Washington to temporarily shield hospitals from losing their 340B eligibility during the COVID-19 pandemic.

Drug industry vendor Kalderos is urging leaders in Washington to temporarily shield hospitals from losing their 340B eligibility during the COVID-19 pandemic.

“Kalderos is urging a rapid federal response to protect these hospitals,” the company said in a July 23

Read More »

For 340B Hospitals, Some Consolation in Otherwise Disappointing CMS Drug Reimbursement Rule

CMS proposes extending "pass-through" status for 24 drugs and three biosimilars in 2022—a move that would temporarily shield the medicines from the deep payment cut for 340B hospitals.

Hospitals groups were deeply disappointed last week with the U.S. Centers for Medicare & Medicaid Services’ (CMS) proposal to continue a nearly 30% cut in Medicare Part B reimbursement for hospitals’ 340B purchased drugs in place since 2018.

Another provision

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live